HYLORIS PHARMACEUTICALS SA NPVHYLORIS PHARMACEUTICALS SA NPVHYLORIS PHARMACEUTICALS SA NPV

HYLORIS PHARMACEUTICALS SA NPV

No trades
See on Supercharts
Market capitalization
‪327.60 M‬EUR
−0.55EUR
‪−15.76 M‬EUR
‪2.81 M‬EUR
‪12.43 M‬
Beta (1Y)
−0.06

About HYLORIS

CEO
Stijn van Rompay
Headquarters
Liege
Founded
2017
ISIN
BE0974363955
FIGI
BBG016JQWXR0
Hyloris Pharmaceuticals SA engages in the development and reformulating of pharmaceutical products. It offers commercial-stage products, Sotalol IV for the treatment of atrial fibrillation; and Maxigesic IV, a novel, dual modeof-action non-opioid analgesic for the treatment of post-operative pain. The company was founded by Stijn van Rompay and Thomas Jacobsen in 2012 and is headquartered in Liege, Belgium.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 0AB6 is 11.70 EUR — it has decreased by 2.50% in the past 24 hours. Watch HYLORIS PHARMACEUTICALS SA NPV stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange HYLORIS PHARMACEUTICALS SA NPV stocks are traded under the ticker 0AB6.
0AB6 stock is 2.56% volatile and has beta coefficient of −0.06. Track HYLORIS PHARMACEUTICALS SA NPV stock price on the chart and check out the list of the most volatile stocks — is HYLORIS PHARMACEUTICALS SA NPV there?
Yes, you can track HYLORIS PHARMACEUTICALS SA NPV financials in yearly and quarterly reports right on TradingView.
0AB6 stock has fallen by 2.50% compared to the previous week, the month change is a 3.55% rise, over the last year HYLORIS PHARMACEUTICALS SA NPV has showed a 12.68% decrease.
0AB6 net income for the last quarter is ‪−9.13 M‬ EUR, while the quarter before that showed ‪−6.63 M‬ EUR of net income which accounts for −37.59% change. Track more HYLORIS PHARMACEUTICALS SA NPV financial stats to get the full picture.
Today HYLORIS PHARMACEUTICALS SA NPV has the market capitalization of ‪327.61 M‬, it has decreased by 0.42% over the last week.
No, 0AB6 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, 0AB6 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HYLORIS PHARMACEUTICALS SA NPV stock right from TradingView charts — choose your broker and connect to your account.
0AB6 reached its all-time high on Apr 20, 2022 with the price of 17.15 EUR, and its all-time low was 11.10 EUR and was reached on Dec 20, 2023. View more price dynamics on 0AB6 chart.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HYLORIS PHARMACEUTICALS SA NPV technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HYLORIS PHARMACEUTICALS SA NPV stock shows the neutral signal. See more of HYLORIS PHARMACEUTICALS SA NPV technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on HYLORIS PHARMACEUTICALS SA NPV future price: according to them, 0AB6 price has a max estimate of 22.10 EUR and a min estimate of 21.00 EUR. Watch 0AB6 chart and read a more detailed HYLORIS PHARMACEUTICALS SA NPV stock forecast: see what analysts think of HYLORIS PHARMACEUTICALS SA NPV and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HYLORIS PHARMACEUTICALS SA NPV EBITDA is ‪−17.54 M‬ EUR, and current EBITDA margin is −615.92%. See more stats in HYLORIS PHARMACEUTICALS SA NPV financial statements.